Literature DB >> 19520196

A prime-boost immunisation regimen using recombinant BCG and Pr55(gag) virus-like particle vaccines based on HIV type 1 subtype C successfully elicits Gag-specific responses in baboons.

Gerald K Chege1, Robin Thomas, Enid G Shephard, Ann Meyers, William Bourn, Carolyn Williamson, James Maclean, Clive M Gray, Edward P Rybicki, Anna-Lise Williamson.   

Abstract

Mycobacterium bovis BCG is considered an attractive live bacterial vaccine vector. In this study, we investigated the immune response of baboons to a primary vaccination with recombinant BCG (rBCG) constructs expressing the gag gene from a South African HIV-1 subtype C isolate, and a boost with HIV-1 subtype C Pr55(gag) virus-like particles (Gag VLPs). Using an interferon enzyme-linked immunospot assay, we show that although these rBCG induced only a weak or an undetectable HIV-1 Gag-specific response on their own, they efficiently primed for a Gag VLP boost, which strengthened and broadened the immune responses. These responses were predominantly CD8+ T cell-mediated and recognised similar epitopes as those targeted by humans with early HIV-1 subtype C infection. In addition, a Gag-specific humoral response was elicited. These data support the development of HIV-1 vaccines based on rBCG and Pr55(gag) VLPs.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19520196     DOI: 10.1016/j.vaccine.2009.05.064

Source DB:  PubMed          Journal:  Vaccine        ISSN: 0264-410X            Impact factor:   3.641


  20 in total

Review 1.  Recombinant Mycobacterium bovis BCG as an HIV vaccine vector.

Authors:  Rosamund Chapman; Gerald Chege; Enid Shephard; Helen Stutz; Anna-Lise Williamson
Journal:  Curr HIV Res       Date:  2010-06       Impact factor: 1.581

2.  Novel recombinant Mycobacterium bovis BCG, ovine atadenovirus, and modified vaccinia virus Ankara vaccines combine to induce robust human immunodeficiency virus-specific CD4 and CD8 T-cell responses in rhesus macaques.

Authors:  Maximillian Rosario; Richard Hopkins; John Fulkerson; Nicola Borthwick; Máire F Quigley; Joan Joseph; Daniel C Douek; Hui Yee Greenaway; Vanessa Venturi; Emma Gostick; David A Price; Gerald W Both; Jerald C Sadoff; Tomás Hanke
Journal:  J Virol       Date:  2010-04-07       Impact factor: 5.103

3.  HIV-1 sub-type C chimaeric VLPs boost cellular immune responses in mice.

Authors:  Sirika Pillay; Enid G Shephard; Ann E Meyers; Anna-Lise Williamson; Edward P Rybicki
Journal:  J Immune Based Ther Vaccines       Date:  2010-11-19

4.  Heterologous Prime-Boost HIV-1 Vaccination Regimens in Pre-Clinical and Clinical Trials.

Authors:  Scott A Brown; Sherri L Surman; Robert Sealy; Bart G Jones; Karen S Slobod; Kristen Branum; Timothy D Lockey; Nanna Howlett; Pamela Freiden; Patricia Flynn; Julia L Hurwitz
Journal:  Viruses       Date:  2010-02-01       Impact factor: 5.048

5.  Robust immunity to an auxotrophic Mycobacterium bovis BCG-VLP prime-boost HIV vaccine candidate in a nonhuman primate model.

Authors:  Gerald K Chege; Wendy A Burgers; Helen Stutz; Ann E Meyers; Rosamund Chapman; Agano Kiravu; Rubina Bunjun; Enid G Shephard; William R Jacobs; Edward P Rybicki; Anna-Lise Williamson
Journal:  J Virol       Date:  2013-02-28       Impact factor: 5.103

Review 6.  Applications of bacillus Calmette-Guerin and recombinant bacillus Calmette-Guerin in vaccine development and tumor immunotherapy.

Authors:  Yuan-qiang Zheng; Youssef W Naguib; Yixuan Dong; Yan-chun Shi; Shorgan Bou; Zhengrong Cui
Journal:  Expert Rev Vaccines       Date:  2015       Impact factor: 5.217

Review 7.  Chronic Immune Activation in TB/HIV Co-infection.

Authors:  Riti Sharan; Allison N Bucşan; Shashank Ganatra; Mirko Paiardini; Mahesh Mohan; Smriti Mehra; Shabaana A Khader; Deepak Kaushal
Journal:  Trends Microbiol       Date:  2020-04-22       Impact factor: 17.079

8.  Dual neonate vaccine platform against HIV-1 and M. tuberculosis.

Authors:  Richard Hopkins; Anne Bridgeman; Joan Joseph; Sarah C Gilbert; Helen McShane; Tomáš Hanke
Journal:  PLoS One       Date:  2011-05-13       Impact factor: 3.240

9.  Stability studies of HIV-1 Pr55gag virus-like particles made in insect cells after storage in various formulation media.

Authors:  Alisson Lynch; Ann E Meyers; Anna-Lise Williamson; Edward P Rybicki
Journal:  Virol J       Date:  2012-09-18       Impact factor: 4.099

10.  Pre-clinical development of BCG.HIVA(CAT), an antibiotic-free selection strain, for HIV-TB pediatric vaccine vectored by lysine auxotroph of BCG.

Authors:  Narcís Saubi; Alice Mbewe-Mvula; Ester Gea-Mallorqui; Maximillian Rosario; Josep Maria Gatell; Tomáš Hanke; Joan Joseph
Journal:  PLoS One       Date:  2012-08-21       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.